Oropharyngeal Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against oropharyngeal cancer and guarantee the finest results for our customers all over the world.

Oropharyngeal Cancer

Oropharyngeal cancer (OPC) is a cancer arising from the throat (oropharynx) tissues. The oropharynx is in the middle of the throat, including the tongue base, tonsils, soft palate and pharyngeal wall. Oropharyngeal cancer can be divided into two categories, HPV-positive and HPV-negative. HPV-positive OPC is related to human papillomavirus infection while HPV-negative OPC is usually associated with alcohol or tobacco use. Signs and symptoms may include pain or difficulty with swallowing, cough, sore throat, voice changes, ear pain and a lump in the back of the throat, mouth or neck. The risk factors which can increase the risk of oropharyngeal cancer include alcohol, smoking, chewing tobacco and betel quid, HPV infection, as well as certain genetic changes. People with HPV-positive oropharyngeal cancer tend to have higher survival rates. The prognosis of patients with oropharyngeal cancer depends on the age, health, and stage of the disease.

Preventive HPV Vaccines for Oropharyngeal Cancer

The incidence of head and neck squamous cell carcinoma (HNSCC), an entity historically caused by tobacco and alcohol exposure, has decreased over the past 30 years. However, the incidence of oropharyngeal cancer, a subset of HNSCCs, has risen significantly. This dramatic rise in OPC is driven by HPV. Approximately 70-90% of newly diagnosed OPCs in the United States are HPV-related. These HPV-related cancers are often seen in younger, healthier patients, many of whom are non-smokers. In the face of this changing epidemiology, there is increasing interest in the potential impact of HPV vaccines on the prevention of OPC.

Most individuals who become exposed to HPV will mount an antibody response and clear the virus. The natural antibody capsid protein, as HPV early genes do not induce an antibody response. It is unclear whether antibodies induced by natural infection with HPV will be protective against reinfection. Preventive vaccines were developed primarily to eradicate cervical cancer and other anogenital malignancies, but these vaccines are likely to dramatically reduce HPV-related oropharyngeal carcinoma as well. The vaccines include virus-like particles (VLPs) resembling the L1 capsid protein, and unlike natural infection, vaccination introduces these VLPs to the lymphatic system.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the oropharyngeal cancer vaccines. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.